References
- Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003;37:944–50.
- Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse- transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102–8.
- Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011: 354908.
- Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001;20:641–8.
- Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297–304.
- Izzedine H, Thibault V, Valantin MA, Peytavin G, Schneider L, Benhamou Y. Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?AIDS 2010;24:1078–9.
- James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004;24:415–8.
- Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070–3.
- Wanner DP, Tyndall A, Walker UA. Tenofovir-induced osteomalacia. Clin Exp Rheumatol 2009;27:1001–3.
- Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482–7.
- Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005;6:341–6.
- Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716–23.
- Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171–7.
- Madeddu G,Quirino T,Carradori S,Ricci E,Grosso C,Penco G, et al. [Renal toxicity in HIV-infected patients receiving HAART including tenofovir]. Infez Med 2006; 14:125–34.
- De Socio GV, Fabbriciani G, Massarotti M, Messina S, Cecchini E, Marasini B. Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required. Mediterr J Hematol Infect Dis 2012;4:e2012025.
- Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009;23:1519–9.
- Klassen K, Martineau AR, Wilkinson RJ, Cooke G, Courtney AP, Hickson M. The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity. PLoS One 2012;7:e44845.
- de la Prada FJ,Prados AM, Tugores A,Uriol M,Saus C,Morey A. [Acute renal failure and proximal renal tubular dysfunction in a patient with acquired immunodeficiency syndrome treated with tenofovir]. Nefrologia 2006;26: 626–30.
- Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez- Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23: 689–96.
- Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment—case report and review of literature. J Infect 2005;51:E61–5.